Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.1 USD | -3.03% | -0.98% | -32.83% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.83% | 1.46B | C | ||
-5.10% | 182B | C+ | ||
-4.01% | 103B | C | ||
-5.39% | 66.94B | A | ||
+10.68% | 46.73B | B- | ||
-7.78% | 45.14B | B- | ||
+5.82% | 41.57B | B+ | ||
+16.63% | 30.48B | B | ||
+14.00% | 24.26B | A- | ||
-6.37% | 23.58B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ATEC Stock
- Ratings Alphatec Holdings, Inc.